pembrolizumab

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

pembrolizumab
Aug 17, 2024, 08:50 | Insight
Karl Semaan: Our study on first-line systemic therapy after adjuvant immunotherapy in RCC
Karl Semaan, Postdoctoral Oncology Research Fellow at Dana-Farber Cancer Institute, shared a post on X…
Aug 14, 2024, 13:49 | Insight
Amol Akhade: New and exciting data coming up at WLCC 24
Amol Akhade shared on X about recent papers: "What's new and exciting data coming up…
Aug 12, 2024, 14:02 | Blog
Stephen Liu: WCLC24 abstract titles released
Stephen Liu shared a post on X: "WCLC24 abstract titles released! Don't miss the plenary…
Aug 12, 2024, 07:28 | Dialogues
Immunotherapy in Soft Tissue - 5 min Sarcoma Talk #6 with Sandra D'Angelo
In the new episode of "5 Minute Sarcoma Talk", Dr. Shushan Hovsepyan, the Editor-in-Chief of…
Aug 9, 2024, 13:35 | Blog
Wafik S. El-Deiry: Keep up with drug names mentioned in the NEJM in the last month
Wafik S. El-Deiry shared on X: "For my colleagues on MedTwitter trying to keep up with…
Aug 8, 2024, 15:54 | Blog
Exploring New Horizons in Kidney Cancer Treatment: An Interview with Dr. Ilya Tsimafeyeu
Non-clear cell renal cell carcinoma (nccRCC) is a challenging kidney cancer subtype. Dr. Ilya Tsimafeyeu,…
Aug 3, 2024, 09:08 | Insight
Valerie Yang: Such a pleasure to chair the Sarcoma Track at the Singapore Society of Oncology (SSO) Annual Scientific Meeting 2024
Valerie Yang, Consultant at National Cancer Centre Singapore, shared a post on LinkedIn: "Such a…
Jul 31, 2024, 14:18 | Blog
Formycon announced start of clinical phase III trial for Keytruda biosimilar candidate FYB206
Formycon AG announced that the first patient has been enrolled in the Phase III clinical…
Jul 31, 2024, 07:32 | Insight
Breaking Science in Gastrointestinal Cancers with David Tougeron - ESMO
ESMO shared on LinkedIn: "For ESMO members: Breaking Science in Gastrointestinal Cancers. David Tougeron discusses…
Jul 26, 2024, 19:39 | Insight
Andrea Necchi: Results from the ECHO-307/KEYNOTE-672 study
Andrea Necchi, Associate Professor at Vita-Salute San Raffaele University, shared on X: “IDO1 inhibition was ineffective…
Jul 25, 2024, 00:18 | Blog
Breaking Science in Gastrointestinal Cancers with Kohei Shitara - ESMO
ESMO (European Society for Medical Oncology) shared on LinkedIn: "For ESMO members: Breaking Science in Gastrointestinal…
Jul 24, 2024, 00:59 | Insight
Luca Licata: The fate of immunotherapy trials in breast cancer
Marco Mariani, Resident in Medical Oncology at San Raffaele Scientific Institute, shared a post on X…
Jul 20, 2024, 18:07 | Blog
Tom Powles: More evidence that PD(L)1 re-challenge should be avoided in renal cancer
Tom Powles posted on X/Twitter: "More evidence that PD(L)1 re-challenge should be avoided in renal…
Jul 8, 2024, 05:44 | Insight
Sapna Patel: An important pathway in cancer signaling, including melanoma
The Video Journal of Oncology (VJOncology) shared on LinkedIn: "New from ASCO2024: Phase I trial…
Jul 6, 2024, 05:13 | Insight
Tanja Obradovic: Choosing immunotherapy treatment for early resectable NSCLC
Tanja Obradovic shared on LinkedIn: "Choosing immunotherapy treatment options with PD(L)-1 inhibitors for early resectable non–small…
Jul 3, 2024, 17:29 | Blog
Benjamin Besse: Stop pembro after 2 years?
Benjamin Besse, Head of Clinical Research at Gustave Roussy, shared on X: "Stop pembro after…
Jul 3, 2024, 02:35 | Insight
Rahul Banerjee: Fascinating small Ph2 trial on relapsed or refractory multiple myeloma
Rahul Banerjee, Assistant Professor at UW Medicine, made the following post on X: “Absolutely abscopal…
Jun 26, 2024, 10:24 | Blog
Chandler Park: Which patients would you not give EV-Pembro for 1st line metastatic bladder cancer?
Chandler Park shared on X:               . "Which patients would…
Jun 25, 2024, 13:37 | Insight
Sacituzumab govitecan with or without pembrolizumab in TNBC
The Dana-Farber’s Breast Oncology Center shared on X: "Dana-Farber’s Breast Oncology Center is leading a…
Jun 22, 2024, 17:06 | Drugs
FDA approves pembrolizumab with chemotherapy for advanced/recurrent endometrial carcinoma
Iván R. González, Medical Oncologist at Angeles Puebla Hospital, shared on X/Twitter: "FDA approves pembrolizumab with…
Jun 21, 2024, 12:59 | Dialogues
ASCO24 Updates: Can We Treat Locally Advanced Lung Cancer Without Radiotherapy?
The American Society of Clinical Oncology (ASCO) Annual Meeting is one of the largest and most…
Jun 14, 2024, 09:12 | Blog
CRI: "Immunotherapy prior to surgery could well become a game-changer" - Mark Saunders
Cancer Research Institute (CRI) shared on LinkedIn:       . "According to clinical trial results…
Jun 11, 2024, 06:28 | Blog
Tanja Obradovic: Intriguing results reported at ASCO24
Tanja Obradovic shared a post on LinkedIn: ''What about intriguing results reported at ASCO24? One…
Jun 8, 2024, 06:52 | Blog
Gabriela Burgos: My key takeaways from ASCO 2024
Gabriela Burgos, Associate Research Director- Evidence Generation Lead, RWE at Oracle shared a post on LinkedIn:…
Jun 8, 2024, 06:02 | Insight
Cue Biopharma Presents Updated Data from CUE-101 in Recurrent/Metastatic HPV+ Head and Neck Cancer at the ASCO24
Cue Biopharma, a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively…
Jun 1, 2024, 23:26 | Blog
Vadim Koshkin: Our recent work highlighting a Grey Zone in metastatic urothelial carcinoma after enfortumab vedotin/pembrolizumab
Vadim Koshkin, Assistant Professor at University of California, San Francisco, shared a post on X/Twitter:…
Jun 1, 2024, 22:56 | Insight
Aakash Desai: All set to showcase exciting NSCLC and lung cancer research at ASCO Lung24
Aakash Desai, Assistant Professor at O'Neal Comprehensive Cancer Center at UAB, shared on LinkedIn:   …
Jun 1, 2024, 21:13 | Blog
Bartomeu Massuti on Optó-TROP 01 Lung study at ASCO24
Bartomeu Massuti, Associate Professor at Miguel Hernandez University of Elche, shared a post on X: "Optó-TROP…
May 31, 2024, 10:41 | Blog
Jason A. Mouabbi: Here are my anticipated Top 3 breast cancer presentations for ASCO24
Jason A. Mouabbi, Breast Medical Oncologist at MD Anderson Cancer Center, shared a post on X:…
May 31, 2024, 07:46 | Blog
Shushan Hovsepyan: Sarcoma Sessions at ASCO2024!
Shushan Hovsepyan shared a post on LinkedIn: “Sarcoma Sessions at ASCO2024!   SARC037: Phase II results…
May 25, 2024, 14:40 | Blog
Dr. Mark Ball on the future of kidney cancer treatment - NCI Center for Cancer Research
NCI Center for Cancer Research shared on LinkedIn: "CANCER CURRENTS: In a large clinical trial, treatment…
May 25, 2024, 08:53 | Insight
Sergio Cifuentes: Key potential insights in immunotherapy of maintenance in women with high T-cell Clonality
Sergio Cifuentes, Student Fellow at National Autonomous University of Mexico, shared on X: "Maintenance Pembrolizumab…
May 23, 2024, 13:33 | Insight
Tom Powles: Debate about activity of neoadjuvant vs adjuvant vs both is ongoing
Tom Powles, Director of Barts Cancer Center, shared a post on X: "Neoadjuvant chemo/nivolumab with…
May 23, 2024, 07:58 | Insight
Tom Powles on new ESMO guidelines for renal cancer
Tom Powles, Director of Barts Cancer Center, shared on X: "New ESMO guidelines in advanced papillary…
May 23, 2024, 07:56 | Blog
Chinmay Jani: Let's explore EGFR Exon 20 Insertion NSCLC with a twist of Miami flair!
Chinmay Jani, Clinical Fellow, Hematology & Oncology at University of Miami, made the following post…
May 22, 2024, 11:01 | Blog
Josh Atkins: Identifying Proteomic Risk Factors
Josh Atkins, Senior Cancer Genomic Epidemiologist at the Nuffield Department of Population Health of Oxford…
May 20, 2024, 02:15 | Insight
Tanja Obradovic: Potential of TIGIT inhibitors to boost efficacy of PD(L)-1 inhibitor immunotherapy
Tanja Obradovic shared on LinkedIn: "Questions around potential of TIGIT inhibitors to boost efficacy of PD(L)-1…
May 19, 2024, 14:53 | Insight
Sergio Cifuentes Canaval: KN 189 and 407 - Pooled Analysis of Outcomes
Sergio Cifuentes Canaval, Student Fellow at National Autonomous University of Mexico, shared on LinkedIn: "KN 189…
May 19, 2024, 05:07 | Drugs
First prospective phase 2 study to directly compare two anti-PD-1 antibodies as first-line treatment in advanced NSCLC - Top Science
Top Science shared on X: “This is the first prospective phase 2 study to directly…
May 18, 2024, 06:04 | Blog
Deniz Can Guven: The 1st-in-human phase 1 study on arginase inhibitor INCB001158
Deniz Can Guven, Medical Oncologist at Health Sciences University, Elazığ City Hospital, shared on X/Twitter:…
May 17, 2024, 04:08 | Blog
Dana-Farber’s Breast Oncology Center is leading a study for metastatic triple-negative Breast Cancer
Janice Cowden shared a post by Dana-Farber’s Breast Oncology Center on X/Twitter: "If you, or someone…
May 14, 2024, 09:21 | Drugs
Piotr Wysocki: Pembrolizumab prevents recurrence in BCG-resistant bladder cancer
Piotr Wysocki recently posted on LinkedIn: "Necchi A et al. published a phase II single-arm study…
May 12, 2024, 00:24 | Insight
Karima Oualla: IBCG- AUA Bladder Cancer Forum
Karima Oualla, Professor of Medical Oncology at Hassan II University Hospital, shared a post on LinkedIn:…
May 10, 2024, 14:58 | Blog
Lauren Brown: Another insightful article out of the AURORA collaboration
Lauren Brown, PhD Candidate at Westmead Institute for Medical Research, University of Sydney & Medical…
May 10, 2024, 10:27 | Opinion
Piotr Wysocki: FDG PET can predict response to immunotherapy in melanoma patients
Piotr Wysocki recently posted on LinkedIn: "Anderson TM et al. published the results of a study…
May 7, 2024, 23:04 | Insight
Eric K. Singhi: Our new Clinical Lung Brief Report on 1L testing & management in mNSCLC
Eric K. Singhi shared the following on X: “Our new Clinical Lung Brief Report on…
May 7, 2024, 06:28 | Insight
Elisa Agostinetto: The long and winding road to biomarkers for immunotherapy
Elisa Agostinetto, Clinical Research Fellow at Institute Jules Bordet, shared on LinkedIn: "The long and…
Apr 28, 2024, 12:40 | Blog
Cancer at Cedars-Sinai is now recruiting patients with advanced NSCLC in a clinical trial
Cancer at Cedars-Sinai posted on X/Twitter: "If you have advanced non-small cell lung cancer, you…
Apr 27, 2024, 11:39 | Blog
Akash Maniam: The optimal management of upper tract urothelial carcinoma is far from clear
Akash Maniam, Medical Oncologist at Portsmouth Hospitals University NHS Trust, shared a post by International…
Apr 24, 2024, 09:58 | Insight
KEYNOTE-A18 summarised by Sergio Cifuentes
Sergio Cifuentes, Cancer Research Project Manager at CENEIT México, posted on X/Twitter: ''KEYNOTE-A18. Pembrolizumab + CRT…
Apr 23, 2024, 23:25 | Drugs
Jarushka Naidoo: Pooled 5-year outcomes of Pembrolizumab and Chemotherapy for PDL less than 1% metastatic NSCLC in the Journal of Thoracic Oncology
Jarushka Naidoo shared on X: “Pooled 5-yr outcomes of Pembrolizumab and Chemotherapy  for PDL1<1% metastatic…
Apr 19, 2024, 06:30 | Insight
Summary of KEYNOTE-A18 by Sergio Cifuentes Canaval
Sergio Cifuentes Canaval, Cancer Research Project Manager at CENEIT México, shared on X/Twitter: "KEYNOTE-A18: Pembrolizumab…
Apr 19, 2024, 06:19 | Insight
Sergio Cifuentes Canaval: I'm thrilled to share groundbreaking progress in the treatment of locally advanced cervical cancer (LACC)!
Sergio Cifuentes Canaval, Cancer Research Project Manager at CENEIT México, shared on LinkedIn: "I'm thrilled to…
Apr 18, 2024, 13:55 | Blog
Erman Akkus: How Genetic Testing Revolutionizes Care for Young Breast Cancer Survivors and Advances in Anaplastic Thyroid Carcinoma Treatment
Erman Akkus, Medical Oncology Fellow at Ankara University, shared on X/Twitter: "1. Second primary breast…
Apr 17, 2024, 00:52 | Insight
UHN Research - Can a blood sample be used to predict patient outcomes to cancer immunotherapy drug pembrolizumab?
UHN Research shared on their LinkedIn: "Can a blood sample be used to predict patient…
Apr 16, 2024, 10:57 | Insight
Erman Akkus: 2 studies from JAMA and Thyroid Journal
Erman Akkus, Medical Oncology Fellow at Ankara University, shared on X/Twitter: 1.'' Second primary breast cancer…
Apr 16, 2024, 01:39 | Drugs
Tom Powles reflects on conducting less successful trials in Urothelial Carcinoma
Tom Powles, Director of Barts Cancer Center, recently shared on X: "We have not had…
Apr 15, 2024, 17:01 | Drugs
Elisa Agostinetto: It’s likely that adjuvant Pembrolizumab has a lower impact compared to neoadjuvant Pembrolizumab
Elisa Agostinetto, Research Physician at the Institute of Jules Bordet in Brussels, posted on X/Twitter:…
Apr 15, 2024, 14:38 | Insight
New Paper Alert! Refining Treatment Approaches in Early Breast Cancer Patients with Pathologic Complete Response
Refining Treatment Approaches in Early Breast Cancer Patients with Pathologic Complete Response Authors: Carmine Valenza,…
Apr 14, 2024, 11:39 | Drugs
Nieves Martinez Lago: FDA approvals Tumor-Agnostic drugs
Nieves Martinez Lago, Medical Oncologist at University Hospital Complex of Ferrol, shared on X/Twitter: "FDA…
Apr 14, 2024, 10:45 | Drugs
Final pre-spectified overall survival analysis of CLEAR, a phase III study - summarized by Yuksel Urun
Yuksel Urun, Professor in Department of Medical Oncology at Ankara University School of Medicine, shared…
Apr 14, 2024, 03:52 | Drugs
Piotr Wysocki: CLEAR trial – another study demonstrating that Immunotherapy and TKI combination should not be routinely recommended to favorable-risk RCC patients
Piotr Wysocki, Professor of Medicine and Head of the Department of Oncology at Jagiellonian University…
Apr 12, 2024, 14:08 | Insight
Erman Akkus: Pancreatic cancer clinical trials in AACR24
Erman Akkus, Medical Oncology Fellow at Ankara University, shared on X: "Pancreatic cancer clinical trials…
Apr 12, 2024, 12:37 | Insight
Niklas Klümper: Happy to share our commentary about EV-302
Niklas Klümper, Resident in Urology and Researcher at the Institute for Experimental Oncology at the…
Apr 11, 2024, 08:13 | Drugs
Tom Powles: Disitimab, Vedotin and Pembrolizumab vs chemotherapy with or without Avelumab in advanced Urothelial Carcinoma
Tom Powles, Director of Barts Cancer Center, recently shared on X: “Trial in progress: The…
Apr 10, 2024, 09:52 | Insight
David Pinato: Immunotherapy might become a novel standard of care in intermediate-stage HCC
David Pinato, Director of Developmental Cancer Therapeutics at Imperial College London, shared on LinkedIn: "Immunotherapy…
Apr 10, 2024, 09:32 | Insight
New Article Alert! New Findings on Personalized Vaccine and Pembrolizumab for Liver Cancer Treatment
New Findings on Personalized Vaccine and Pembrolizumab for Liver Cancer Treatment Authors: Mark Yarchoan, Edward…
Apr 5, 2024, 01:51 | Insight
Piotr J. Wysocki: Pembrolizumab significantly improves efficacy of chemoradiotherapy in patients with locally-advanced cervical cancer
Piotr J. Wysocki, Head of the Oncology Department at the University Hospital Krakow, shared a post…
Mar 25, 2024, 15:15 | Societies
25 Posts Not To Miss From ELCC 2024
The European Lung Cancer Congress (ELCC 2024) took place in Prague, Czech Republic, from 20th…
Mar 21, 2024, 17:05 | Blog
Kristina Jenei: I watched IQVIA trends for the next year so you don't have to
Kristina Jenei, Associate Editor at the Journal of Cancer Policy, recently posted on X: "I…
Mar 18, 2024, 19:11 | Blog
Fredrick Chite Asirwa: International Cancer Institute clinic is recruiting breast cancer patients for clinical trials currently
Fredrick Chite Asirwa, CEO/Executive Director of International Cancer Institute, posted on LinkedIn: "To contribute to…
Mar 17, 2024, 19:51 | Insight
Tom Powles: New ESMO's guidlines for advanced bladder cancer Annals of Oncology - Enforumab Vedotin and pembrolizumab is the new standard of care
Tom Powles, Director of Barts Cancer Center, shared a post on X: "New ESMO's guidelines for…
Mar 15, 2024, 15:26 | Insight
Enfortumab+pembrolizumab combination as the 1st line treatment of choice for advanced urothelial cancer - summary by Piotr J. Wysocki
Piotr J. Wysocki, Professor of Medicine, Head of Department of Oncology at Jagiellonian University Hospital,…
Mar 14, 2024, 09:34 | Drugs
Earle Burgess: Analysis of the just published EV-302 study
Earle Burgess, Genitourinary Medical Oncologist, Atrium Health Levine Cancer Institute, shared a post by LinkedIn: "Is…
Mar 11, 2024, 17:58 | Insight
Melvin Chua: Interesting results from LEAP010 - combo Pembro with Levatinib or Carbozatinib
Melvin Chua, Head of the Department of Head Neck and Thoracic Cancers, Division of Radiation…
Feb 2, 2024, 17:33 | Drugs
Day 3 of GU24 ASCO Highlights by Oncology Brothers
Oncology Brothers recently tweeted: "Day 3 of GU24 ASCO Highlights 1. KN564: Adj Pembro w/…
Feb 1, 2024, 17:24 | Drugs
Day 2 of GU24 ASCO Highlights by Oncology Brothers
Oncology Brothers shared on their X/Twitter: "Day 2 of GU24 ASCO Highlights 1. UNITE: EV…
Feb 1, 2024, 15:42 | Opinion
Thomas Powles: Enfortumab Vedotin and Pembrolizumab shows broad spectrum of activity for Regional Recurrence, Progression-free survival and Overall Survival in all subgroups
Jan 29, 2024, 14:47 | Blog
Roberto Iacovelli: Andrea Apolo at GU24 presented results of AMBASSADOR trial
Roberto Iacovelli, Associate Professor of Medical Oncology at Catholic University, Comprehensive Cancer Center of Rome,…
Jan 23, 2024, 10:44 | Insight
Joanna Baginska: The results for a melanoma expansion cohort of a phase 1B, multicenter, open-label study
Joanna Baginska, Lead Scientist at Dana-Farber Cancer Institute, shared a post on LinkedIn: "In this…
Jan 18, 2024, 15:12 | Blog
Maria Natalia Gandur Quiroga: Immuno-Oncology Advances in Genitourinary Cancers
Maria Natalia Gandur Quiroga shared a post on LinkedIn: "Immuno-Oncology Advances in Genitourinary Cancers: Introduction:…
Jan 17, 2024, 19:34 | Drugs
Yüksel Ürün: The U.S. FDA has approved pembrolizumab in combination with chemoradiotherapy for FIGO 2014 Stage III-IVA cervical cancer
Yüksel Ürün, Professor at the Department of Medical Oncology at the Ankara University School of…
Jan 7, 2024, 15:14 | Drugs
Paolo Tarantino: Decades of cancer research converging on new effective treatment options for our patients with HR-positive breast cancer
Paolo Tarantino, Medical Oncologist and Research Fellow at the Dana-Farber Cancer Institute, shared on LinkedIn:…
Jan 5, 2024, 14:54 | Blog
Pavlos Msaouel: Six papers that improved our understanding of Renal Medullary Carcinoma
Pavlos Msaouel, Assistant Professor of Genitourinary Medical Oncology at MD Anderson Cancer Center, recently posted…
Dec 30, 2023, 17:58 | Opinion
Laura Bukavina: Let's dive into the topic of non-muscle-invasive bladder cancer
Laura Bukavina, Urologic Oncologist at University Hospitals Cleveland Medical Center, shared a post on X/Twitter:…
Dec 24, 2023, 18:05 | Insight
Marco Donia: Adjuvant Anti-PD-1 Immunotherapy for Resected Melanoma: Update December 2023
Marco Donia, Associate Professor at National Center for Cancer Immune Therapy, Denmark, shared on LinkedIn:…
Dec 14, 2023, 16:23 | Insight
SABCS23 Day 1 Highlights by Oncology Brothers
Oncology Brothers have recently shared their highlights from SABCS23. Below we feature the first day's…
Dec 12, 2023, 11:42 | Insight
Shruti Jolly: Treating lung cancer with immunotherapy and radiation without chemotherapy
Shruti Jolly, Associate Director for the Statewide Cancer Network at Michigan Medicine, shared on LinkedIn:…
Dec 11, 2023, 11:27 | Insight
Margaret Gatti-Mays: A great option for our patients with TNBC
Margaret Gatti-Mays, Associate Professor in the Division of Medical Oncology at the OSUCCC – James…
Nov 21, 2023, 14:18 | Drugs
5 new drug indications by FDA Oncology in the last 10 days - Oncology Brothers
Quoting Oncology Brothers on X/Twitter: "What just happened? 5 new drug indications by FDA Oncology…
Nov 5, 2023, 18:48 | Drugs
Toni Choueiri: Pembrolizumab hits OVERALL SURVIVAL in KYN-564 adjuvant study in Kidney Cancer!!!
Toni Choueiri, the Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer…
Nov 1, 2023, 14:45 | Blog
Translational Research in Oncology announced the first patient was randomized in the REPLACE (TRIO041) trial
Translational Research in Oncology shared on their LinkedIn page: ''TRIO is happy to announce that…
Oct 26, 2023, 16:27 | Blog
Benjamin Auberger: This major study naturally raises several questions
Quoting Benjamin Auberger, Oncologist at CHRU Brest, on LinkedIn: "A wow presidential session with a…
Oct 24, 2023, 15:36 | Blog
Lucjan Wyrwicz: Grab the most recent issue of the Lancet Oncology with the full report of the Keynote-859 study
Lucjan Wyrwicz, Professor at the National Institute of Oncology Maria Skłodowska-Curie - National Research Institute,…
Oct 24, 2023, 13:45 | Blog
Stephen V Liu: ESMO23 - Dr. Solange Peters presents the PERLA randomized phase II study
Quoting Stephen V Liu, Associate Professor of Medicine and the Director of Thoracic Oncology at Georgetown University,…
Oct 23, 2023, 15:26 | Insight
Tom Powles: Enfortumab vedotin and Pembrolizumab improving PFS and OS by 55% and 53% respectively compared to platinum based chemo in 1st line UC (+avelumab in 30%)
Tom Powles, Director of Barts Cancer Centre, shared on Twitter: "Enfortumab vedotin and Pembrolizumab improving…
Oct 21, 2023, 19:37 | Blog
Amol Akhade: Do we need to study every new IO drug against Pembrolizumab plus chemo in first line NSCLC? NO.
Amol Akhade, Senior Consultant in Medical and Hematooncology at the Dr Hitendra Patil's Suyog Cancer…
Oct 21, 2023, 19:24 | Opinion
Olubukola Ayodele: Day 1 of ESMO 2023 was all about early breast cancer (EBC) for me today
Olubukola Ayodele, Consultant Medical Oncologist at University Hospitals of Leicester NHS trust, shared on LinkedIn:…
Oct 18, 2023, 16:43 | Drugs
U.S. FDA approved pembrolizumab for NSCLC as single-agent for adjuvant and in combination with chemo for neoadjuvant settings - American Association for Cancer Research
American Association for Cancer Research recently shared on its Twitter page: "Today, the U.S. FDA…
Sep 7, 2023, 19:34 | Blog,Drugs,Insight
Shruti Patel: Tumor Board Tuesday - Mini tweetorial.
Shruti Patel, Oncology Fellow at Stanford Health Care, recently tweeted: "Tumor Board Tuesday - Mini…
All: 203 Posts: 101 - 200
Special Coverage